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 The European Association for the Study of Obesity (EASO) considers obesity to be a 
health, research, and societal priority  [1] . It promotes the study of obesity. Moreover, the 
EASO facilitates and engages in actions that reduce the burden of unhealthy excess weight in 
Europe through prevention as well as management and prevent and combat the epidemic of 
obesity. 
 Although overweight and obesity are considered the 5th leading risk for death globally 
according to the WHO  [2] , clear opportunities for diagnosis and, consequently, treatment are 
being missed  [3] . The EASO recently published a position statement in which the significance 
of obesity was re-defined as a rising public health, clinical, and scientific challenge in Europe. 
Obesity is a ‘gateway’ for many other diseases, such as dyslipidemia, hypertension, diabetes, 
and vascular disease  [1] . Obesity should therefore be seen as one of the main targets for 
current efforts to combat the increasing non-communicable disease (NCD) epidemic  [4] . 
Consequently, redefined obesity treatment strategies were also published  [5] . In line with 
EASO’s commitment to improve and guarantee an appropriate, comprehensive treatment 
quality for obese patients, criteria for EASO collaborating centers on obesity management 
(EASO-COMs) have been published  [6] , and the network has successfully been rolled out and 
is rapidly growing throughout more than 30 countries in Europe.
 For the treatment of obesity and its co-morbidities, effective weight loss and subse-
quent weight maintenance are of particular importance. With a mean weight loss effect 
below 5%, simple lifestyle approaches alone do not help the majority of cases reach 
treatment targets. The only reimbursed medical alternative today is bariatric surgery which 
is (according to European guidelines) indicated for type 2 diabetics with obesity grade II 
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and for all obesity grade III patients. Bariatric surgery allows for a clinically significant 
mean weight loss above 15% of initial body weight. There is an important gap in the 
treatment options to achieve weight loss of up to 15% in obesity grade I subjects and over-
weight patients with co-morbidities. Lifestyle intervention in combination with drugs could 
fulfill this role. In Europe we lack therapeutic options available elsewhere, particularly the 
USA. There are a number of new drugs registered in the USA which are included in recently 
published US guidelines  [7] .
 Role of Weight Management in Patient Therapy 
 In brief, weight management is not only important in itself but regarded as essential in 
the management of concomitant diseases. While the long-term goal of obesity management 
is to reduce morbidity and mortality, there are numerous short-term benefits. Obesity 
management leads to marked improvements in blood glucose control, hypertension, dyslip-
idemia, and other co-morbidities like osteoarthritis as well as to a reduction in the risk (and 
severity) of obstructive sleep apnea. As excessive weight plays also an important role in the 
development of cancer, gout and depression, treatment of obesity could be beneficial or at 
least preventive in their further deterioration  [8] . Successful weight loss has also been shown 
to improve quality of life, mobility, daily function, and psychological well-being; pharmaco-
therapy may potentiate these effects. Many of these drugs are purported to operate by 
strengthening endogenous energy regulation systems and moderating appetite sensations. 
These have the potential to help the obese gain better control over their eating behavior, and 
limit their energy intake, making weight management easier. Given the negative psycho-
logical consequences of dieting (cravings, obsession with food, dysphoria, and cognitive 
impairment) and the physiological effects of energy restriction (reductions in endogenous 
GLP-1 and leptin associated with hunger), such pharmaceutical approaches might have 
profound effects on patients’ experience of weight management. 
 Targets of Weight Management in Overweight and Obesity 
 Obesity is a complex condition of multifactorial origin with key internal and external 
drivers. This multifactorial origin not only explains the rise in prevalence across distinct 
populations but also individual variation within these. Biological susceptibility combined 
with psychological and social/situational factors promote weight gain, and deleterious 
outcomes are associated with adiposity. Obesity management should no longer focus solely 
on body weight (and BMI) reduction  [9] . Given the role of body composition in obesity-related 
ill health; attention should be paid to a reduction of waist circumference or waist-to-hip ratio 
(especially in females) and the improvement in body composition (measured with body 
composition tracking systems like air-displacement plethysmography, dual energy X-ray 
absorptiometry, or bioelectrical impedance analysis), with a main focus on ameliorating or 
maintaining fat-free mass and decreasing fat mass  [1, 2] . In some patients, especially in those 
who are overweight (BMI 25.0–29.9 kg/m 2 ), but also in older patients, prevention of further 
weight gain (through dietary advice and increase in physical activity) rather than weight loss 
per se may be an appropriate target. Weight loss objectives should always be realistic, indi-
vidualized, and aimed at the long term. A practical weight loss objective of 5–10% over a 
period of 6 months is realistic and has a proven health benefit  [1, 2] . A greater weight loss 
may be considered for those with greater degrees of obesity (BMI  ≥ 35 kg/m 2 , obesity grade 
II and III).
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 Maintenance of weight loss as well as prevention of new and treatment of current 
co-morbidities constitute the three main criteria for success. Obesity is a chronic disease for 
which follow-up and continued supervision is necessary lifelong in order to monitor disease 
risks, treat co-morbidities (e.g., type 2 diabetes mellitus, cardiovascular disease), and prevent 
weight regain  [10] .
 The Present Status of Anti-Obesity Treatments 
 Treatment should be individually tailored, and clinical care providers should be able to 
provide a wide spectrum of clinically proven treatment options and combinations of them, 
for example:
 – Individual or group lifestyle modification  
 – Lifestyle modification including dietary supplements (such as very low calorie diets 
(VLCDs))  
 – Addition of anti-obesity drugs 
 – Addition of bariatric surgery. 
 Lifestyle intervention is the basis for the treatment of overweight and obesity, whenever 
possible. When performed by trained and specialized personnel, such treatment has improved 
considerably, at least in patients who are ‘manageable’. This improvement is due to the devel-
opment of transdisciplinary approaches, including dietary, exercise and behavior modifica-
tions, while also considering psychosocial characteristics of patients.
 Pharmacological treatment should only be considered as part of a comprehensive strategy 
of disease management  [11] . However, as an adjunct pharmacotherapy can help patients to 
maintain compliance, ameliorate obesity-related health risks, and also improve their quality 
of life  [12] . By supporting body weight reduction, these drugs  also appear beneficial in 
preventing the development of obesity-related co-morbidities (e.g. type 2 diabetes mellitus). 
Drugs should be used according to their licensed indications and restrictions. Currently, drug 
therapy is recommended for patients with a BMI  ≥ 30 kg/m 2 or a BMI  ≥ 27 kg/m 2 with an 
obesity-related co-morbidity (e.g. hypertension, type 2 diabetes mellitus). The efficacy of 
pharmacotherapy should be evaluated after the first 3 months of therapy (responders). If 
weight loss is considered satisfactory (>5% weight loss in patients without and >3% in 
patients with diabetes), treatment should be continued. Improvements in waist circum-
ference and/or body composition could also be used as alternative, more realistic, indicators 
for success. Treatment should be discontinued in non-responders, or – if possible – an alter-
native therapy should be used  [5] .
 Currently, the options for obesity pharmacotherapy worldwide vary. In Europe, the only 
available approved drug for weight management is orlistat. This triglyceride lipase inhibitor 
reduces fat absorption by 30%. Given that its site of action is within the gastrointestinal tract, 
its expected gastrointestinal side effects may have behavioral consequences in terms of the 
avoidance of energy-dense high-fat foods  [13] . Orlistat is available in two dosages: 120 mg 
t.i.d. (prescription) and 60 mg t.i.d. (OTC). In combination with a hypocaloric low-fat diet it is 
adding a mean effect of 3–4% supplementary weight loss to the lifestyle intervention  [14] 
which may appear modest, but in responder subgroups such effect might be higher. The 
published data demonstrate efficacy and safety over a period of 4 years  [15] . Importantly, 
orlistat has a beneficial effect on blood pressure, LDL-cholesterol, and insulin resistance 
resulting in improvements of blood glucose. This effect contributes significantly to the 
prevention of type 2 diabetes  [11, 16, 17] .
 While bariatric metabolic surgery is a far more effective intervention in terms of weight 
loss (15–40% weight loss of initial body weight), it is invasive and may not be appropriate for 
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the majority of patients; moreover its widespread use may be limited due to the high number 
of patients. Thus there is a significant need for more effective noninvasive treatment options 
bridging the gap between lifestyle modifications plus orlistat and surgical interventions. A 
number of new drugs for weight management are currently being tested in clinical trials 
worldwide  [18] . Such medications could serve as new treatment options. In future, a poly-
therapeutic strategy may possibly rival surgery concerning efficacy, safety, and achievements 
of weight loss  [19] .
 Medical Treatment for Obesity – Regulatory Update 
 With this unsatisfactory situation in mind, in 2012 the US Food and Drug Administration 
(FDA) registered two new drugs (lorcaserine and an extended-release topiramate/phen-
termine combination)  [20] and, recently (September 2014), a third one, namely a combi-
nation of naltrexone and bupropion. 
 Lorcaserin (10 mg b.i.d.) is a selective serotonin 5-HT 2C agonist that regulates food intake 
 and results in approximately 3–4% of body weight loss  [21] . The drug is the latest in a long 
line of 5-HT-based approaches to control appetite. 5-HT 2C agonism, along with 5-HT release 
and re-uptake inhibition, has been shown to suppress hunger and strengthen satiety. Despite 
historical issues of safety with regard to serotoninergic drugs, at present the safety profile of 
lorcaserin is regarded to be acceptable, at least where it is licensed. Thus, the drug may be an 
interesting treatment option, especially in 12-week responders revealing good weight loss of 
approximately 10 kg after 1 year  [22] . However, the drug has not been approved in Europe. 
It is the opinion of the Committee for Medicinal Products for Human Use (CHMP) that, based 
on the current evidence, the benefits of the drug did not outweigh its risks. 
 The second drug is an extended-release combination  of two well-known drugs topi-
ramate and phentermine, using 23/46 and 92 mg of topiramate and 3.75/7.5 and 15 mg of 
phentermine. This drug combination is designed to suppress appetite and enhance satiety 
although clinical data demonstrating an appetite reduction of these drugs, either individually 
or in combination, is lacking. Indeed, the modes of action of topiramate on energy intake are 
still poorly understood. However, this novel drug combination is efficacious, showing a weight 
reduction of approximately 10%, and is regarded as a safe treatment option  [23] . Recently it 
has been demonstrated that this combination is also able to prevent diabetes in a pre-diabetic 
population  [24, 25] . However, this drug combination has not been approved in Europe. In 
2012 and 2013 the CHMP voted against the approval of this topiramate/phentermine combi-
nation on the basis ‘that the long-term safety of this combination, particularly in the cardio-
vascular and psychiatric areas, had not been completely defined.’ It should be noted that the 
development program for these agents included a 2-year study, met the size and duration 
requirements set by the EMA; moreover, these drugs are not unknown quantities as the single 
agents have been on the market around the world and used by millions of patients for more 
than 15 years for a variety of indications. However, although given at lower doses, any combi-
nation of known CNS-acting drugs could produce synergistic effects and discrete psycho-
logical phenomenona that may not be detected by standard adverse events reporting. None-
theless, using standing approved monitoring methods the safety profile of topiramate/phen-
termine in its development program did not reveal anything new as compared to the existing 
approved monotherapy product labels. On the other hand, the weight loss and other benefits 
of treatment, including reduction in blood pressure and improvements in other important 
cardiovascular and metabolic biomarkers, were well demonstrated  [20] . Further monitoring 
of the cardiovascular events of the combined therapy (post-marketing surveillance on new 
trails) should in time address these concerns. In the light of the withdrawal of rimonabant, 
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the CHMP concerns may be taken in account that EMA requirements should be revised for all 
centrally acting agents to improve the detection of rare and serious psychiatric events. Well 
validated psychometric tools and experimental tests exist for such a purpose.
 The third drug available in the USA is again a combination. Naltrexone is an opioid antag-
onist for the treatment of opioid and alcohol dependency, whereas bupropion is a norepi-
nephrine/dopamine re-uptake inhibitor used to treat depression and smoking cessation. 
Opioid antagonists have been demonstrated to decrease hunger and specifically the palat-
ability of preferred foods (using tasty sweet and /or high fat foods associated with high energy 
density). The effects of bupropion on human appetite have yet to be adequately characterized 
although its effects on appetite could be mediated by dopaminergic reward mechanisms. 
Naltrexone 8–32 mg and bupropion 90–360 mg in combination (NB32), although ineffective 
as individual monotherapies for obesity, produce weight loss and a metabolic profile bene-
ficial for the potential treatment of obesity. According to current data  [26] , the efficacy of this 
combination seems slightly less than that of topiramate/phentermine but superior to orlistat 
and lorcaserin. It has to be stated that there is a FDA warning label addressing rare and but 
severe psychiatric side effects which must be acknowledged. With regard to approval in the 
EU, the CHMP has raised many additional questions that the company had to answer  [27] . 
Specifically, the CHMP requested further justification of the balance of benefits and risks of 
NB32 treatment as well as additional information regarding post-approval risk minimization 
measures and pharmacovigilance activities. Finally the CHMP has voted for the drug combi-
nation in December 2014, and we look forward to the final decision by the European 
Parliament.
 Another promising drug for obesity treatment is the GLP-1 agonist liraglutide. GLP-1 infu-
sions produce reliable reductions in energy intake through decreases in pre-meal hunger and 
the strengthening of post-meal satiety which are effects sometimes seen with GLP-1 analogues 
and agonists  [28] . This GLP-1 agonist has been extensively studied in type 2 diabetes and is 
marketed as a treatment of it in many countries worldwide. Some patients do exhibit side 
effects, mainly nausea at the beginning of the therapy (which clearly may lead to discontinu-
ation in that phase). Nonetheless, the safety profile of the drug over the long term appears 
excellent. As obesity and diabetes are so inter-linked as disorders, widening the indication for 
liraglutide use to obesity in pre- or non-diabetic populations may be reasonable  [29, 30] . In a 
study using liraglutide 3 mg once daily for obesity treatment, a weight loss of approximately 
6% was achieved, with even better performance when applied after a VLCD  [31] .
 In the USA, liraglutide (0.6–1.8 mg) is available for diabetes treatment since 2010. An 
FDA advisory panel has voted 14 to 1 in favor of liraglutide for the treatment of obesity 
resulting in a subsequent approval by the FDA. The drug is also under consideration within 
the European regulatory process. 
 A recent review of all these pharmaceutical agents stated that all potentially available 
drugs could facilitate weight reduction as treatments  [32] . However, their most important 
clinical contribution could be the prevention of weight regain after effective non-pharmaco-
logically induced weight loss  [33] . This approach could include sustaining the effects of other 
interventions such as VLCD together with lifestyle management or more focused behavioral 
support. These comprehensive approaches have the potential to produce large and long-
lasting benefits for the patient. However, the current regulatory environment focusses on 
weight loss rather than weight regain prevention. 
 Outcome Studies  
 Cardiovascular (CV) outcome studies are currently not required for approval of obesity 
drugs. However, in the past and present CV outcomes seem to attract particular attention also 
in obesity drugs. In a population that in any case is at great risk of CV outcomes, drug effects 
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that could potentiate this risk clearly pose a problem. It is important to note that recent 
clinical trials on obesity drugs, designed within the current regulatory frame of short- to 
medium-term use lasting up to 2 years, have not revealed any safety concerns with regard to 
either topiramate/phentermine or lorcaserin .  Guidelines formulated by the EASO with the 
aim to facilitate the decision making regarding the use of obesity drugs of course should be 
based on clinical evidence. Therefore, appropriately designed CV safety studies should be 
conducted for new obesity agents pre or post approval. Only in those drugs with no effect on 
validated markers of CV risk or a mechanistic rationale making CV effects extremely unlikely 
(e.g., orlistat that acts within the gastrointestinal tract and is not absorbed), an additional CV 
safety study seems to be dispensable pre  or post approval.
 CV outcome studies are costly in terms of time. So, in order to allow for an fast access to 
new therapies for patients in need, an approval decision should take into consideration if a 
drug showed clear and beneficial effects on validated surrogates of CV risk in phase II or 
phase III trials. The relationship between surrogate risk and endpoint outcome is not simple, 
especially if the trial does not model actual clinical practice both in prescribing and continu-
ation. For example, sibutramine, which today is no longer licensed for clinical use, showed to 
elevate blood pressure in the pre-approval phase. This surrogate finding was eventually 
confirmed by increased incidence of hard CV endpoints in the SCOUT trial. However, the 
SCOUT trial itself included of a high number of patients with at least one contra-indication for 
sibutramine at baseline, a population the drug was not intended for  [34] . Interestingly, it has 
recently been found that rapid weight loss and marked blood pressure reduction in the 
beginning of the SCOUT trial increased CV events in patients with cardiovascular disease  [35] . 
It should also be noted, unlike in clinical practice, that patients not exhibiting weight loss 
(non-responders) remained in the study. This is important as a recent detailed analysis of the 
SCOUT study demonstrated that, while the sibutramine group experienced more primary 
outcome events than the placebo group, greater weight loss reduced overall risk of these 
occurring in both groups  [36] .
 The regulatory balance is of course difficult to strike. CV problems have caused consid-
erable concern in the past, and this has persuaded regulators to look critically at a number of 
new agents. Beyond the clear imperative of safety, potential CV risks of drugs must be 
addressed in order to make sure that patients have confidence in the treatment and conse-
quently benefit from pharmacotherapy. However, a potential requirement for demonstration 
of long-term CV safety before approval for all obesity drugs not only clearly restricts avail-
ability of new agents for obese patients but also stifle further advances in the obesity field 
which may lead to next-generation therapeutics. The FDA is currently following cardiologic 
expert advice and is asking for appropriate post-approval outcome studies  [37, 38] . This, in 
conjunction with the effective use of validated surrogates pre approval, should reduce the 
likelihood of adverse CV outcomes and allow potentially effective treatments to reach patients 
far sooner. In Europe, the mandatory requirement for pre-approval CV outcome studies is 
highly problematic considering that only few effective treatments for obesity are available. 
This does not mean that CV outcome studies generally should not be done but that high-risk 
populations where the drugs in any case would be contra-indicated should be excluded in 
order to reflect clinical use of a drug also in the pre-approval risk assessment. 
 Next Steps  
 In Europe, we are currently facing a situation in which high prevalence rates of over-
weight and obesity collide with a scenario in which effective pharmaceutical treatments are 
unavailable. The time has come to initiate regular discussions regarding the cardiometabolic 
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risks of pharmaceutical obesity therapy with key stakeholders and decision makers throughout 
Europe at the EU and country level. Through this we may gain both a wider understanding of 
the extent of the obesity epidemic and a deeper appreciation of urgent unmet medical needs 
in the management of obesity. Clearly this discussion must be evidence-based. The risk-
benefit ratio within the European context is of paramount importance. But risks that cannot 
be assessed within existing clinical trials as the patient groups included do reflect a selected 
target population for such a drug therapy should not be a prerequisite for drug approval. Even 
though they must be addressed in additional appropriate studies, a post-clinical assessment 
seems to be sufficient and justified. 
 The EASO therefore calls on the European Commission, the European Parliament, the 
CHMP, and all member states to work together to ensure that new obesity treatment options 
can be more readily available in order to eliminate the extensive unmet medical needs in this 
area to the benefit of European citizens and society. This does not mean that we abandon the 
risk-benefit model but that we plead for adapting it systematically and effectively to the 
approval and regulatory process. A platform of measures and tools already exists than can 
be deployed pre and post approval to assess risk in intended populations. If we are successful 
in managing obesity, we will block a key progression route of many major chronic diseases. 
A progress in the treatment of obesity would be a major social and economic achievement 
and of personal significance for the millions of obese individuals and their families seeking 
help.
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